Zydus’ generic of hormone therapy patch gets U.S. FDA nod

The product is eligible for the 180-day exclusivity period available to certain first approved applicants under the CGT pathway, subject to the provisions of the U.S. Federal Food, Drug, and Cosmetic Act.
Read the full story on The Hindu Opens thehindu.com in a new tab
Advertisement
CallZenixAI Voice Bot, Dialer & IVR SolutionsCloud dialer and contact-center software for your teamKnow more
This is a short summary of a story published by The Hindu, shown with a link to the original. The full story, photo and reporting belong to The Hindu.











